Survival Data
WHY WE ARE SO SUCCESSFUL
Our commitment to the highest quality standard has enabled our program to continue to outperform year after year.
We specialize in caring for high-risk and complicated patients in comparison with other centers that may select only favorable-risk patients.
Only attending BMT-focused physicians are involved in patient care versus residents, fellows, clinician-researchers, or physicians whose primary interest lies outside of blood and marrow transplant.
Our BMT physicians take first call on nights and weekends to provide immediate access.
Our highly organized and proactive Quality Improvement Program has served as a national model for other transplant centers.
Seven consecutive triannual inspections by the Foundation for Accreditation of Cellular Therapy (FACT) found no detected deficiencies in the clinical program, which is an unprecedented accomplishment.
A high ratio of dedicated BMT pharmacists-to-patients prevents medication errors and ensures adherence to evidence-based algorithms.
Northside is the ONLY adult BMT program in the U.S. that achieved survival outcomes that significantly exceeded their expected one-year survival rate for the last 17 consecutive reporting cycles (2009–2025). It is the largest allogenic program in Georgia and the ONLY transplant center in Georgia to exceed survival outcomes.
“As the only program to reach this milestone, it reflects the excellence of care, high-quality standards, and the dedication of the entire team,” said Dr. Melhem Solh, a physician at The Blood & Marrow Transplant Group of Georgia and the medical director of Northside’s Cellular Therapy Program. “Patients are offered access to a top-level, patient-centered program that includes innovative research and clinical trials designed to support them throughout their journey.”
“Northside Hospital has built outstanding support teams, including critical care, cardiology, surgical specialties, and infectious diseases, all working collaboratively to help patients achieve some of the best survival outcomes following transplantation,” Dr. Solh added.
Innovative treatments and research are major components of the NH-BMT. Northside offers chimeric antigen receptor (CAR) T-cell therapy, TIL therapy, and other immunotherapy treatment options, including novel clinical research trials.
